Sahajanand Medical Technologies IPO

Lot size and investment

Reservation

QIB

67,86,058 shares (50.00% of the Offer)

NII

20,35,817 shares (15.00% of the Offer)

Retail

47,50,241 shares (35.00% of the Offer)

Employee

2,50,000 shares (1.81% of the Offer)

Current GMP

₹17

▲+4.94%

Estimated listing price

₹361

Issue price ₹344

Highest

₹43

15 Oct

Lowest

₹15

17 Oct

GMP by day (₹ per share)

Subject to sauda

₹500 retail · ₹7,000 HNI

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

P/E (pre-issue)

57.91

P/E (post-issue)

57.91

EPS (₹)

5.94

RoE

2.07%

RoCE

3.16%

RoNW

2.31%

PAT Margin

4.29%

EBITDA Margin

13.81%

Debt / Equity

0.33

NAV (₹)

64.35

Pre-issue P/E uses the shares outstanding before the IPO; post-issue P/E includes the new shares. Calculated by Be IPO Ready at the issue price.

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

How Sahajanand Medical Technologies plans to use the money raised, as stated in the offer document.

1. Offer for sale by the selling shareholders. The company receives no proceeds from the offer

Sahajanand Medical Technologies Ltd. was founded in 2001 by Dhirajlal Kotadia. It is a medical device company focused on Class III and Class C/D devices, mainly for vascular and structural heart intervention. It was the first company in the world to get CE certification for a drug-eluting stent with a biodegradable polymer, called Infinnium. The products fall in three groups. Vascular intervention covers coronary stents and balloons. Structural heart covers TAVI and occluders. Other products include renal stents, peripheral drug-coated balloons and some trading products. The company has two R&D centres, one in India and one in Thailand, with 102 professionals. It holds 102 granted patents globally and has 71 pending applications. Key brands are Supraflex Cruz, Hydra (TAVI) and Cocoon (occluders), backed by 72 clinical studies and sold in over 76 countries. It sells directly in Germany, Spain, France and the UK, uses a hybrid model in India and distributors in markets such as Italy. As of 31 March 2025 it had 1,458 full-time staff, 24 consultants and 818 contract personnel.

Promoters and shareholding

Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen and Shree Hari Trust

Promoter holding, pre-issue

40.82%

Promoter holding, post-issue

36.2%